A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)

Phase 3 Not yet recruiting 198 enrolled West China Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

This Phase III randomized trial, evaluates whether adding targeted radiation (SBRT) and an immunotherapy drug (Serplulimab) to standard chemotherapy (GnP) can extend the lives of patients with advanced pancreatic cancer.

Timeline

Start: 2026-02
Primary completion: 2027-07
Completion: 2028-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Serplulimab	Monoclonal antibody	—	—
Background	Gemcitabine	Small molecule	—	—
Background	Paclitaxel	Small molecule	—	—

A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)

Summary

Timeline

Drugs

Indications